Customized Aptamer-conjugated LNP development services for cell-targeted payload delivery, aptamer surface engineering, ligand density optimization, and targeted delivery evaluation.
Aptamer-conjugated LNPs are lipid nanoparticles engineered with DNA or RNA aptamers on the surface. These aptamers can recognize selected cell-surface targets and help guide nanoparticles toward specific cell types. A successful aptamer-LNP needs more than simple surface decoration. The aptamer sequence, terminal modification, linker length, lipid anchor, surface density, LNP composition, and payload loading method must work together. BOC Sciences helps pharmaceutical and biotechnology researchers design, optimize, and characterize aptamer-displaying lipid nanoparticles for siRNA, mRNA, ASO, guide RNA/mRNA combinations, proteins, peptides, small molecules, imaging probes, and other research payloads.
Aptamer Conjugated LNP Structure IllustrationBOC Sciences provides integrated Aptamer-conjugated LNP development services covering aptamer screening, aptamer optimization, aptamer-lipid conjugation, LNP formulation integration, physicochemical characterization, targeting validation, and process development for targeted payload delivery research.
Our team helps identify, refine, and stabilize aptamers with suitable binding performance for later LNP surface display.
We design aptamer-lipid structures and coupling routes that support stable and accessible aptamer presentation on LNP surfaces.
The formulation workflow integrates aptamer surface ligands with the LNP core to balance ligand accessibility, payload loading, and particle stability.
Integrated analytical support evaluates aptamer display, particle attributes, payload retention, morphology, and formulation integrity for clear candidate comparison.
Targeting studies verify whether aptamer modification improves target binding, cellular uptake, tissue distribution, and functional payload activity.
Our process support helps improve larger-scale preparation, batch consistency, aptamer display reproducibility, and formulation handling for continued research use.
Aptamer-LNP development requires both aptamer chemistry and LNP formulation control. BOC Sciences combines ligand design, lipid conjugation, controlled nanoparticle preparation, surface density optimization, and biological evaluation to help researchers select better aptamer-LNP candidates.
Develop aptamer-modified LNPs with optimized ligand chemistry, surface density, particle attributes, payload loading, and target-cell delivery performance.
BOC Sciences supports aptamer-modified LNP development for many payload types used in targeted delivery research. Each payload type has different loading, stability, and readout requirements. We help clients match aptamer surface design with payload properties and LNP formulation needs.
| Payload Type | Supported Uses & Aptamer-LNP Development Considerations | Request Information |
|---|---|---|
| Aptamer-LNP Development for siRNA | Suitable for target-cell gene-silencing research. Development focuses on siRNA encapsulation, free siRNA reduction, aptamer density control, target-cell uptake, and knockdown comparison in suitable in vitro models. | Inquiry |
| Aptamer-LNP Development for mRNA | Designed for protein expression, reporter expression, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, particle stability, aptamer exposure, and expression readouts in target-relevant cell systems. | Inquiry |
| Aptamer-LNP Development for ASO and Oligonucleotides | Supports ASO, miRNA, and modified oligonucleotide payloads that require LNP-based protection and targeted cellular entry. Development focuses on payload charge behavior, retention, aptamer-lipid compatibility, and separation of free versus particle-associated material. | Inquiry |
| Aptamer-LNP Development for gRNA/mRNA | Applicable to co-loaded nucleic acid systems such as guide RNA/mRNA combinations. Development focuses on co-encapsulation ratio, payload integrity, particle uniformity, aptamer surface display, and target-cell functional readout design. | Inquiry |
| Aptamer-LNP Development for Protein and Peptide | Suitable for enzymes, binding proteins, protein antigens, functional peptides, and peptide-like molecules used in targeted delivery studies. Development focuses on mild loading, aggregation control, activity retention, and surface adsorption reduction. | Inquiry |
| Aptamer-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules that may benefit from targeted LNP delivery. Development considers drug-lipid compatibility, loading route, leakage control, release behavior, and aptamer-mediated uptake comparison. | Inquiry |
| Aptamer-LNP Development for Imaging and Tracking | Supports fluorescent dyes, labeled RNA, labeled proteins, reporter payloads, and other tracking agents used to study binding, uptake, localization, and biodistribution trends. Development focuses on signal retention and assay compatibility. | Inquiry |
| Aptamer-LNP Development for Custom Payload | Developed for projects involving multiple payloads, unusual molecular formats, or early feasibility testing. BOC Sciences can evaluate loading sequence, payload compatibility, aptamer modification method, and target-cell delivery performance. | Inquiry |
Aptamer-LNP development often fails when ligand chemistry, surface density, particle formulation, and biological readout are optimized separately. BOC Sciences helps clients connect these steps and select candidates based on combined particle and delivery data.
✔ Weak Target-Cell Uptake Improvement
Aptamer-LNPs may show weak uptake improvement when the aptamer is hidden by PEG, attached at an unsuitable site, or displayed at a poor density. We optimize spacer length, conjugation position, aptamer density, and PEG-lipid ratio to improve target-accessible presentation.
✔ Loss of Aptamer Binding After Conjugation
Aptamer folding can be disrupted by terminal modification, short linkers, or surface crowding. We review the aptamer structure, test alternative terminal designs, and compare spacer options to help preserve target recognition after conjugation.
✔ Particle Size Increase After Aptamer Modification
Aptamer-lipid components can disturb LNP self-assembly and cause larger particles or broad PDI. We rebalance ionizable lipid, helper lipid, cholesterol, PEG-lipid, and aptamer-lipid levels to restore particle uniformity.
✔ Reduced Payload Encapsulation
Surface modification may change the self-assembly environment required for nucleic acid loading. We adjust lipid composition, aqueous phase condition, payload input, and mixing parameters for nucleic acids encapsulation in LNPs.
✔ Unclear Aptamer-Specific Contribution
Uptake data can be difficult to interpret without strong controls. We prepare matched unmodified LNPs, scrambled aptamer-LNPs, target-positive cell models, and target-low cell models to help identify aptamer-related effects.
✔ Uptake Without Strong Functional Delivery
High uptake does not always lead to effective payload activity. We evaluate intracellular localization, RNA activity, reporter expression, or gene silencing. When needed, projects can include LNP endosomal escape evaluation.
BOC Sciences helps research teams troubleshoot aptamer binding loss, unstable particle size, low payload loading, weak target-cell uptake, and unclear functional delivery readouts.
The project starts with a clear discussion of your target cell type, receptor of interest, aptamer sequence, payload type, desired readout, and expected LNP attributes. We also review your preferred surface modification route, control groups, and evaluation model. Based on these details, BOC Sciences prepares a practical aptamer-LNP development plan.
We design the aptamer modification strategy according to the target, payload, and formulation goal. This may include terminal modification, spacer length selection, lipid anchor design, conjugation chemistry selection, and aptamer density range planning. The design aims to keep the aptamer accessible while maintaining LNP stability.
BOC Sciences prepares aptamer-LNP candidates using post-insertion, co-formulation, or covalent surface coupling. During optimization, we adjust lipid composition, aptamer-lipid ratio, PEG-lipid level, payload loading, mixing condition, buffer exchange, and purification method. Matched control LNPs are prepared when needed.
Each candidate is evaluated for particle size, PDI, zeta potential, payload loading, aptamer density, free aptamer level, and formulation integrity. We can also support in vitro, ex vivo, or in vivo research-model evaluation for binding, uptake, localization, expression, gene silencing, or distribution trends. The final data help clients compare candidates and select a practical formulation direction.
BOC Sciences supports aptamer-modified LNP development for targeted delivery research in oncology, inflammation, autoimmune disease, cardiovascular disease, neurodegenerative disease, infectious disease, and ophthalmic disease models. Each application can be customized according to the selected aptamer, payload type, target cell, and delivery evaluation method.
Challenge: A biotechnology research team wanted to develop an aptamer-modified LNP for delivering a gene-editing tool across a blood-brain barrier model. The payload contained Cas nuclease mRNA and sgRNA. The first LNP formulation showed acceptable RNA encapsulation, but uptake in brain endothelial cells was weak. The client also needed to know whether the aptamer improved BBB-relevant transport rather than only increasing non-specific nanoparticle binding.
Diagnosis: The initial aptamer-LNP had three main problems. The aptamer density was too low to support strong receptor engagement. The PEG-lipid layer partly shielded the aptamer from the target receptor. The formulation was tested only in one endothelial cell model, so the targeting contribution could not be clearly separated from general LNP uptake.
Solution: BOC Sciences redesigned the aptamer-LNP screening plan around BBB-targeting performance. Our team compared three aptamer-lipid densities, two PEG spacer lengths, two PEG-lipid ratios, and two ionizable lipid compositions. Matched unmodified LNPs and scrambled aptamer-LNPs were prepared as controls. Candidate formulations were tested in receptor-positive brain endothelial cells, receptor-low control cells, and an in vitro transwell BBB model. Free aptamer blocking was also used to verify receptor-related uptake.
Result: The selected BBB-crossing aptamer-gene editing tool LNP maintained particles around 85-120 nm with PDI below 0.22, while total RNA encapsulation remained above 75%. In receptor-positive brain endothelial cells, uptake increased about 2.6-fold compared with the unmodified LNP control. Uptake was much lower in receptor-low control cells, and free aptamer blocking reduced uptake by nearly 50%. In the transwell BBB model, the optimized aptamer-LNP showed stronger apical-to-basolateral transport than both the unmodified LNP and scrambled aptamer-LNP controls. The client obtained a clearer candidate for brain-targeted gene-editing delivery research.
Challenge: A research group was developing a solid tumor-targeted aptamer-siRNA LNP for silencing a tumor-associated transcript in receptor-positive cancer cells. The starting formulation showed good siRNA encapsulation, but the uptake difference between target-positive and target-low cells was small. Gene-silencing data were also inconsistent, making it difficult to confirm whether the aptamer improved tumor-cell-selective delivery.
Diagnosis: The aptamer was likely displayed at an unsuitable surface density. A high PEG-lipid level reduced ligand accessibility, while increasing aptamer-lipid input caused larger particles and broader PDI. The study also lacked a scrambled aptamer-LNP control and a receptor-blocking design, so the targeting mechanism was not clear.
Solution: BOC Sciences built a targeting-focused formulation matrix for the aptamer-siRNA LNP. We screened four aptamer-lipid densities, two PEG spacer designs, two PEG-lipid ratios, and three lipid-to-siRNA input conditions. Candidate LNPs were evaluated for particle size, PDI, zeta potential, siRNA encapsulation, aptamer surface density, serum stability, target-cell uptake, and siRNA knockdown. Receptor-positive tumor cells, receptor-low control cells, scrambled aptamer-LNPs, and free aptamer competition groups were included to confirm targeting specificity.
Result: The optimized solid tumor-targeted aptamer-siRNA LNP used a moderate aptamer density and a longer spacer to improve receptor-accessible presentation. The final candidate showed particles around 90-115 nm with PDI below 0.20 and siRNA encapsulation above 80%. In receptor-positive tumor cells, uptake increased about 2.8-fold compared with the unmodified LNP control, while uptake in receptor-low cells remained limited. Free aptamer competition reduced target-cell uptake by about 45%, supporting aptamer-mediated recognition. The selected formulation also produced stronger gene silencing in target-positive tumor cells than in control cells.
Integrated Aptamer and LNP ExpertiseBOC Sciences combines aptamer modification, conjugation chemistry, LNP formulation, payload loading, and targeting evaluation. This helps clients avoid disconnected optimization steps.
Clear Service SegmentationOur services cover aptamer selection, chemical modification, aptamer-lipid conjugate development, LNP surface modification, formulation screening, characterization, and cell-targeted delivery evaluation.
Payload-Compatible Formulation DesignWe design aptamer-LNP formulations according to payload properties. Supported payloads include RNA, oligonucleotides, proteins, peptides, small molecules, imaging agents, and custom payload combinations.
Data-Guided Candidate SelectionWe compare candidates using both physicochemical data and biological readouts. This helps clients select formulations based on particle quality, aptamer display, uptake, and functional delivery performance.
Flexible Support for Custom ProjectsBOC Sciences supports early feasibility testing, formulation troubleshooting, control LNP preparation, ligand density screening, and targeted delivery validation. The service scope can be adjusted to each project goal.
Aptamer-modified LNPs are designed for targeted delivery when a standard lipid nanoparticle shows insufficient selectivity toward the desired cell population. By displaying a DNA or RNA aptamer on the LNP surface, the formulation can recognize specific membrane receptors, transporters, tumor-associated markers, immune-cell markers, or tissue-related binding targets. This approach is especially useful for siRNA, mRNA, circRNA, gRNA/mRNA combinations, proteins, peptides, small molecules, and imaging payloads that require stronger target-cell engagement. For drug discovery teams, the value of aptamer-modified LNPs is not only improved uptake, but also clearer comparison between receptor-mediated delivery and non-specific nanoparticle internalization.
Aptamer selection should consider target binding affinity, receptor accessibility, sequence length, folding stability, terminal modification compatibility, nuclease resistance, and whether the aptamer remains functional after lipid conjugation or surface coupling. A strong free aptamer may perform poorly on an LNP if its binding domain is sterically blocked, if the spacer is too short, or if the surface density changes its structure. BOC Sciences can help evaluate aptamer candidates according to the target cell model, payload type, LNP composition, and expected readout. The development strategy may include aptamer sequence comparison, terminal modification design, linker screening, density adjustment, and matched control LNP preparation to identify a practical targeting configuration.
Yes. Aptamers are charged and structurally sensitive nucleic acid ligands, so their incorporation may influence particle size, PDI, zeta potential, surface hydration, payload retention, colloidal behavior, and storage stability. Too much aptamer on the surface may increase aggregation or create an unfavorable interaction with serum proteins, while too little aptamer may fail to improve target-cell recognition. The key is to optimize the LNP core and aptamer surface layer together. During development, formulation scientists usually compare different aptamer-lipid conjugates, PEG spacer lengths, coupling methods, ligand densities, and lipid ratios. A suitable candidate should maintain acceptable particle attributes while showing improved uptake and functional payload activity in the target model.
Aptamer-mediated targeting should be validated with a structured control design rather than relying only on higher fluorescence uptake. Useful controls may include unmodified LNPs, scrambled aptamer-LNPs, free aptamer competition, receptor-high and receptor-low cell models, and different aptamer density variants. Analytical readouts can include flow cytometry, confocal imaging, receptor competition, intracellular localization, and payload function such as mRNA expression or siRNA knockdown. BOC Sciences can support this evaluation by connecting formulation attributes with biological readouts, helping clients understand whether the observed effect comes from true aptamer-receptor recognition, general nanoparticle uptake, altered particle surface properties, or downstream intracellular delivery limitations.
Common challenges include weak target-cell uptake, loss of aptamer binding after conjugation, unstable particle size after modification, reduced payload encapsulation, unclear receptor contribution, and strong uptake without sufficient functional activity. These problems often occur because aptamer design, linker length, surface density, LNP composition, and payload release are treated as separate issues. In practice, they must be optimized as one integrated delivery system. BOC Sciences supports aptamer-modified LNP development through aptamer surface engineering, formulation screening, payload-compatible preparation, physicochemical characterization, and cell-based delivery evaluation. This helps research teams compare candidates with clearer decision points and select formulations that better match their target cell and payload requirements.
